Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	OSPREY MEDICAL INC.	
ABN	ARBN 152 854 923	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Sandra Lesenfants
Date of last notice	15 May 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A	
Date of change	10 May 2019 (AEST)	
No. of securities held prior to change	211,833	Options with exercise price of A\$0.38 per Share
	Total: 211,833 Options (exercisable into an equivalent of 423,666 CDIs)	
Class	Options over Shares (not quoted)	
Number acquired	*40,000 Options (exercisable into an equivalent of 80,000 CDIs)	
Number disposed	Nil	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil	

⁺ See chapter 19 for defined terms.

No. of securities held after change	211,833	Options with exercise price of A\$0.38 per Share
	40,000*	Options with exercise price of A\$0.26 per Share
	Total: 251,833 Options (exercisable into an equivalent of 503,666 CDIs)	
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	*Issue of Options to Sandra Lesenfants was in accordance with the Osprey Medical 2016 Stock Incentive Plan. The grant of Options was approved by stockholders on 9 May 2019 as part of the Company's Annual Stockholder meeting.	

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Appendix 3Y Page 2 01/01/2011

⁺ See chapter 19 for defined terms.

Part 3 – *Closed period

Were the interests in the securities or contracts detailed above	No
traded during a ⁺ closed period where prior written clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.